What is the significance of a peripheral eosinophil count of 14.9% and what work‑up is recommended?

Peripheral Eosinophil Count of 14.9%: Clinical Significance and Work-Up

A peripheral eosinophil count of 14.9% requires immediate calculation of the absolute eosinophil count (AEC) to determine severity and guide investigation—if the AEC is ≥0.5 × 10⁹/L, this confirms eosinophilia and mandates systematic evaluation for helminth infections (especially in travelers/migrants), allergic conditions, drugs, and less commonly malignancy or vasculitis. 1

Immediate First Steps

Calculate the Absolute Eosinophil Count

• Multiply 14.9% by the total white blood cell count to get AEC
• Eosinophilia definition: AEC > 0.5 × 10⁹/L 1
• Hypereosinophilia definition: AEC ≥ 1.5 × 10⁹/L 1
• This distinction is critical—hypereosinophilia is rarely explained by allergy alone and always requires extensive work-up 2

Assess for End-Organ Damage (URGENT)

Any evidence of end-organ damage requires urgent medical assessment and emergency treatment consideration 1. Specifically evaluate for:

• Cardiac involvement: Heart failure symptoms, chest pain, arrhythmias
• Pulmonary involvement: Dyspnea, infiltrates on imaging
• Neurological involvement: Altered mental status, focal deficits, encephalopathy
• Skin involvement: Rashes, nodules, ulcerations

Persistent eosinophilia at any level can cause significant damage to heart, lungs, and central nervous system 1.

Systematic Diagnostic Approach

Essential History Elements

Travel and Migration History:

• Recent travel to or residence in endemic areas (particularly sub-Saharan Africa, Southeast Asia, Latin America)
• Helminths are the commonest identifiable cause in travelers/migrants (19-80% of cases) 1
• Specific attention to West Africa exposure (for filariasis) 1

Medication Review:

• Complete list of all medications including over-the-counter and supplements
• Drugs are among the most common non-infectious causes in low-endemic areas 1

Allergic/Atopic History:

• Asthma, eczema, hay fever, food allergies
• Atopic diseases are the most frequent diagnosis across all eosinophilia severity groups 3

Symptoms Suggesting Specific Etiologies:

• GI symptoms: Abdominal pain, diarrhea (helminth infections, eosinophilic GI disorders)
• Respiratory symptoms: Wheezing, cough, dyspnea (asthma, ABPA, eosinophilic pneumonia)
• Skin manifestations: Rashes, pruritus, nodules
• Constitutional symptoms: Fever, weight loss, night sweats (malignancy, vasculitis)

Recommended Investigations

First-Line Testing for Asymptomatic Eosinophilia

For Travelers/Migrants 1:

• Helminth serology (Strongyloides, Schistosoma, Filaria)
• Stool microscopy × 3 samples for ova, cysts, and parasites
• Filarial serology only if West Africa exposure (day/night blood films no longer recommended first-line) 1
• Complete blood count with differential
• Basic metabolic panel, liver function tests

For Non-Travelers in Low-Endemic Areas:

• Review for allergic/atopic conditions
• Comprehensive medication review
• IgE levels (total and specific allergen testing if indicated)
• Chest X-ray if respiratory symptoms

Additional Testing Based on AEC Level

If AEC 1.5-5.0 × 10⁹/L (Moderate):

• All first-line tests above
• Consider ANCA testing (for EGPA)
• Serum tryptase (systemic mastocytosis)
• Vitamin B12 level
• HIV testing

If AEC ≥5.0 × 10⁹/L (Severe) 1:

• All above tests
• Bone marrow biopsy with cytogenetics
• FISH for FIP1L1-PDGFRA fusion (myeloid variant HES)
• PDGFRB mutation testing
• Echocardiogram and troponin (cardiac assessment)
• CT chest/abdomen/pelvis (lymphadenopathy, organomegaly)
• Consider lymph node biopsy if lymphadenopathy present

Critical Pitfall

If AEC ≥1.5 × 10⁹/L persists for >3 months without identified cause and no end-organ damage, refer to hematology for further investigation 1. Do not assume allergy alone explains hypereosinophilia.

Empirical Treatment Considerations

For Asymptomatic Eosinophilia in Travelers/Migrants

If age >24 months and travel/migration history present, empirical treatment is recommended 1:

• Albendazole 400 mg single dose PLUS
• Ivermectin 200 μg/kg single dose

This approach is particularly appropriate when:

• Helminth serology pending or unavailable
• Patient from endemic area
• No contraindications to therapy

Treatment Response Monitoring

• Repeat AEC in 4-6 weeks after empirical therapy
• Resolution in approximately 50% of empirically treated cases 4
• Persistent eosinophilia requires completion of diagnostic work-up

High-Risk Conditions Requiring Specific Attention

Strongyloides stercoralis

• Can persist lifelong and cause fatal hyperinfection syndrome in immunocompromised patients 1
• Mortality is high if hyperinfection develops 1
• Always test and treat if any risk of exposure

Schistosoma haematobium

• Associated with squamous cell bladder carcinoma 1
• Long-term oncologic risk mandates treatment

Hypereosinophilic Syndrome (HES)

• If AEC ≥1.5 × 10⁹/L for >6 months with end-organ damage and no identifiable cause
• Requires hematology referral
• May need corticosteroids or targeted therapy (imatinib for FIP1L1-PDGFRA positive cases)

EGPA (Eosinophilic Granulomatosis with Polyangiitis)

• Consider if: asthma + eosinophilia + systemic vasculitis features
• ANCA testing indicated
• Requires rheumatology involvement

Follow-Up Strategy

For Mild Eosinophilia (0.5-1.5 × 10⁹/L):

• Repeat AEC in 4-6 weeks
• If persistent, complete diagnostic work-up
• If resolving, consider reactive/transient cause

For Hypereosinophilia (≥1.5 × 10⁹/L):

• Close monitoring every 2-4 weeks until cause identified
• Serial assessment for end-organ damage
• Mandatory hematology referral if persists >3 months without identified infectious cause 1

For Identified Helminth Infection:

• Treat appropriately
• Repeat AEC 4-6 weeks post-treatment to confirm resolution
• Persistent elevation suggests treatment failure, reinfection, or alternative diagnosis